New treatments for recurrent ATRT brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests new treatments for children and young adults whose ATRT brain tumor has come back or grown. It aims to find if these therapies can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ATRT (a rare brain tumor) with loss of a specific protein (SMARCB1 or SMARCA4).
- The tumor must have come back or gotten worse after prior treatment.
- Age must be between 1 and 39 years old.
- You must be able to do daily activities with some help (score of 50 or higher on a standard scale).
- Blood tests must show that your bone marrow, kidneys, and liver are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
This trial tests a treatment that targets tumor blood-vessel growth to slow or shrink relapsed/progressive brain tumors in children. It may help if standard options are no longer working.
This trial tests a new type of immunotherapy called CAR T cells—immune cells engineered in the lab to fight a specific brain tumor called ATRT (atypical teratoid rhabdoid tumor). The cells are designed to recognize and attack tumor cells that have a protein called GPC3, and are enhanced with immune-boosting signals to work better.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Hear when a new Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.